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Background: ADPKD affects approximately 1:1000 of the worldwide population. It is caused by mutations in two
genes, PKD1 and PKD2. Although allelic variation has some influence on disease severity, genic effects are strong,
with PKD2 mutations predicting later onset of ESRF by up to 20 years. We therefore screened a cohort of ADPKD
patients attending a nephrology out-patient clinic for PKD2 mutations, to identify factors that can be used to offer
targeted gene testing and to provide patients with improved prognostic information.
Methods: 142 consecutive individuals presenting to a hospital nephrology out-patient service with a diagnosis of
ADPKD and CKD stage 4 or less were screened for mutations in PKD2, following clinical evaluation and provision of
a detailed family history (FH).
Results: PKD2 mutations were identified in one fifth of cases. 12% of non-PKD2 patients progressed to ESRF during
this study whilst none with a PKD2 mutation did (median 38.5 months of follow-up, range 16–88 months, p< 0.03).
A significant difference was found in age at ESRF of affected family members (non-PKD2 vs. PKD2, 54 yrs vs. 65 yrs;
p< 0.0001). No PKD2 mutations were identified in patients with a FH of ESRF occurring before age 50 yrs, whereas a
PKD2 mutation was predicted by a positive FH without ESRF.
Conclusions: PKD2 testing has a clinically significant detection rate in the pre-ESRF population. It did not accurately
distinguish those individuals with milder renal disease defined by stage of CKD but did identify a group less likely
to progress to ESRF. When used with detailed FH, it offers useful prognostic information for individuals and their
families. It can therefore be offered to all but those whose relatives have developed ESRF before age 50.Background
ADPKD is an important monogenic cause of renal
disease worldwide, affecting more than 1:1000 of the
population. It accounted for 6.7% of incident cases in
the UK in 2009 requiring RRT and 9.6% of the prevalent
cases (UK Renal Registry, http://www.renalreg.com).
The development of ESRF typically occurs in later life,
although there is considerable inter- and intra-familial
variability [1]. Factors that have some minor predictive
value for disease severity and earlier onset of ESRF* Correspondence: fek1000@cam.ac.uk; rns13@cam.ac.uk
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reproduction in any medium, provided the orinclude male sex, early age of diagnosis, early onset
hypertension, and macroscopic haematuria [2]. Therefore
it is difficult to provide accurate prognostic information
to affected individuals and their at-risk family members.
Although clinical trials are in progress, there are no
current therapies that have been shown to alter the course
of the disease and the rate of decline in renal function [3].
ADPKD is caused by mutation of one of two genes,
PKD1 or PKD2 (MIM 601313 and 613095). Other rare
genetic causes for multiple renal cysts are well recog-
nised but are typically clinically distinct from ADPKD
[4]. Initial studies suggested that approximately 85% of
cases of ADPKD are due to PKD1 mutations with the
remainder in PKD2 [5]. However several recent studies
have suggested that PKD2 mutations may be present in
up 36% of cases depending on the population screenedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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many individuals, PKD2-linked disease is mild and they
either do not present or come late to medical attention
[2,6]. This is supported by studies reporting that patients
with PKD2 mutations develop ESRF some 15–20 years
later than those with a PKD1 mutation (69 yrs vs 53 yrs
respectively) [7,8]. As further clinically useful within-
gene genotype-phenotype correlations do not exist, this
genic effect is one of few major predictors of clinical se-
verity in ADPKD [9]. Clinical indicators of disease sever-
ity such as magnetic resonance-measured renal volume
have been proposed as important, both in monitoring
early progression and in providing more accurate long
term predictions of outcomes such as ESRF before a
decline in GFR is evident, but are currently confined to
research use [10,11].
PKD gene testing has recently been approved for clin-
ical use in the UK by the UK Genetic Testing Network
(www.ukgtn.nhs.uk) and is available in other countries
worldwide. To provide improved prognostic and genetic
counselling information, we introduced PKD2 mutation
testing into a hospital nephrology outpatient service that
sees pre-ESRD patients, as a clinical tool to assign
patients and their families to either PKD2 or non-PKD2
groups. PKD2 testing has the potential to provide accur-
ate genotype information for an individual without the
need to collect additional family members for linkage
analysis or to undertake the more complex and technic-
ally challenging PKD1 mutation testing [12,13]. ADPKD
patients attending a single nephrology outpatient clinic
formed the study cohort, which excluded those already
referred to a low clearance clinic (CKD5) or already re-
ceiving RRT. Here we show that direct PKD2 mutation
testing offers a means of providing additional prognostic
information to individuals with ADPKD and their fam-










Barua et al. 2009 [25] 26 Single centre, ESRF excluded
Peters et al. 1992 [5] 15 Multi-centre, ADPKD kindreds
Rossetti et al. 2007 [12] 15 Multi-centre, CRISP study
(GFR >70 ml/min)
Rossetti et al. 2003 [26] 12 Multi-centre, ADPKD with
vascular phenotype
Garcia-Gonzalez
et al. 2007 [22]
15 Multi-centre, ESRF included
This study 20 Single centre, CKD5 and
ESRF excludedMethods
Clinical assessment
Sequential unrelated adults referred to the Cambridge
Renal Genetics and Tubular Disorders Clinic (http://www.
cuh.org.uk/addenbrookes/services/clinical/renal/services/
renal_genetics_tubular_disorders_clinical.html) between
2005 and 2009 with, or at risk of, a primary clinical diag-
nosis of ADPKD were included in this study. Patients
attending other clinics such as low clearance (CKD5,
eGFR ≤ 15 mL/min/1.73 m2) or renal replacement/trans-
plant clinics were excluded. Standard diagnostic ultra-
sound criteria were used if there was a known family
history of ADPKD [14]. If no family history was avail-
able, the diagnosis of ADPKD was made if renal im-
aging demonstrated bilateral nephromegaly with
multiple cortical and medullary cysts with or without
hepatic/pancreatic cysts, and where other diagnoses
associated with bilateral renal cysts were excluded. Clin-
ical and family data was obtained from index cases dur-
ing their routine clinical assessment. Additional family
data, where necessary, was obtained from medical
records with full written consent. The following demo-
graphic and clinical data were collected: age, gender,
blood pressure, antihypertensive treatment, serum cre-
atinine/eGFR at presentation, indications for renal ultra-
sound, current renal function, initiation of dialysis and/
or death, number of affected relatives and age of their
ESRF. Hypertension was defined as a blood pressure
> 140/90 mmHg on more than one occasion, or regular
prescription of antihypertensive medication. Renal vol-
ume was not routinely evaluated.
This study was approved by the Cambridge Central
Research Ethics Committee (project number 08/H0306/62)
and registered for audit activity with Cambridge University
Hospitals NHS Foundation Trust.
Mutation detection
Genomic DNA from all index cases was extracted by
standard methods and screened for PKD2 mutations by
exon-specific PCR and direct sequencing. Further
details of the methods used are available in Additional
file 1: Table S1 or via the UKGTN website (http://
www.ukgtn.nhs.uk/gtn/Home). PKD2 sequence variants
were defined as pathogenic if either previously reported
or destructive to the integrity of the encoded protein,
and if mis-sense, as likely pathogenic/likely neutral
using the criteria described in the PKD Mutation data-
base (www.pkdb.mayo.edu).
Statistical analysis
All data are presented as mean± SE or median (IQR) as
appropriate. Comparisons of proportions were made
with Fisher’s Exact or Mann Whitney U test. Continuous
variables were compared with the Student’s t-test or
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<0.05 was considered significant. Patients were included
in analyses of renal function if their creatinine values
were available for two or more time points. Rate of de-
cline in renal function was assessed using response fea-
ture analysis [15], with the regression slope of eGFR
over age as the response feature. CKD stages 3–5 were
defined as the first time point when eGFR reached
standard threshold criteria on three consecutive mea-
surements. Time to onset of CKD was assessed using a
Cox proportional hazards model, with PKD genotype as
the predictor variable. The proportional hazard assump-
tion was assessed using scaled Schoenfeld residuals [16].
For building proportional hazard models, goodness of fit
was assessed by estimating the empirical Nelson-AalenTable 2 Sequence variants identified in PKD2
Exon Mutation designation cDNA change Amin
1 E95X c.283 G> T Glu95
1 P150L c.449 C> T Pro15
1 A190T c.568 G>A* Ala19
1 305_307dupAGG c.305_307dupAGG Val 10
1 397del44 c.397del44 Ser13
1 401_410delTGGGCGCGCG c.401_410delTGGGCGCGCG Val13
2 W201X c.602 G>A* Trp20
2 R213X c.637 C> T Arg21
IVS2 IVS2 + 5insA c.709 + 5insA Leu23
IVS2 IVS2-2A>G c.710-2A>G* Leu23
4 R322Q c.965 G>A* Arg32
4 R361X c.1081 C > T* Arg36
IVS4 IVS4 + 1 G>A c.1094 + 1 G>A* Ala36
5 G390V c.1169 G> T Gly39
6 F482C c.1445 T >G* Phe48
6 W507X c.1521 G>A Trp50
7 1668dupA c.1668dupA Gln55
IVS8 IVS8 + 5 G>C c.1898 + 5 G>C Leu57
IVS8 IVS8 + 1 G>A c.1898 + 1 G>A* Leu57
8 Q613X c.1837 C > T Gln61
8 C632Y c.1895 G>A Cys63
10 2085_2087delAGCinsGG c.2085_2087delAGCinsGG Lys69
11 2163dupC c.2163dupC Val72
11 R730Q c.2189 G>A Arg73
11 R742X c.2224 C > T* Arg74
13 R807Q (a) c.2420 G>A* Arg80
14 R845X c.2533 C > T* Arg84
14 L867P (a) c.2600 T > C Leu86
15 D919N c.2755 G>A Asp91
1-15 EX1_EX15del
* =mutations already described in the PKD mutation database (www.pkdb.mayo.edcumulative hazard function with the Cox-Snell residuals
as the time variable, along with the censoring variable [17].
All primary analyses using regression models were per-
formed using diagnostic sub-type as the only predictor
variable. All analyses were performed using Stata SE
v11.2, (College Station, Texas).
Results
PKD2 mutation detection
142 individuals with ADPKD were studied. We identified
PKD2 mutations in 27 (19%). Identified sequence var-
iants are listed in Table 2. Twenty-five different patho-
genic or likely pathogenic PKD2 mutations were
identified in 27 cases, with an additional one being inde-
terminate according to the PKD Mutation Database.o acid change Mutation type Significance No. of cases
X nonsense pathogenic
0Leu missense likely neutral
0Thr missense likely neutral 4
3 fs frameshift pathogenic
3fs frameshift pathogenic
4fs frameshift pathogenic
1X nonsense pathogenic 2
3X nonsense pathogenic 2












2Tyr missense likely pathogenic
5fs frameshift pathogenic
2fs frameshift pathogenic




7Pro missense likely pathogenic
9Asn missense likely pathogenic
deletion pathogenic
u) (a) = both variants found in the same patient.
A 
B 
Figure 1 Indications for ultrasound screening at time of
diagnosis as given by clinician. Number of subjects in each
category are shown. Total non-PKD2= 115; PKD2= 27. UTI = urinary
tract infection; SAH= subarachnoid haemorrhage.
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(42%; 6 small insertions/deletions and 5 splice site
alterations), 5 were substitutions (19%), and 1 whole
gene deletion was found (4%). Nine (35%) had beenFigure 2 (A) Distribution of mutations along the PKD2 coding sequen
pathogenic mutations identified from the PKD mutation database. Other =
(B) Percentage of total PKD2 mutations (red); each exon's percentage of thpreviously described in the PKD Mutation database. The
mutations identified more than once were all found in
unrelated probands. The whole gene deletion was ini-
tially identified by FISH following the previous identifi-
cation of a presumed balanced translocation within the
family (46,XX,t(4;11)(q22;q21); manuscript in prepar-
ation). Its significance was confirmed by array CGH
and MLPA showing haploinsufficiency for PKD2 that
segregated in all family members with ADPKD (data
not shown). Combining the 27 mutations identified in
this study with the 115 pathogenic mutations listed in
the PKD database with this study (20% of the total),
Figure 1 shows the proportion of mis-sense and other
mutations in each exon, and their distribution along the
encoded protein. No mutation hotspots were apparent.
The majority (87%) are predicted to be inactivating, in
keeping with previous studies [18]. In addition, 4 neu-
tral amino acid substitutions (two novel) were found in
eight individuals (Table 2). These subjects were classi-
fied as 'non-PKD2'.
One patient harbouring a mis-sense mutation had
a second, indeterminate change, R807Q (Table 2).
Although his mother was clinically affected, parental
samples were not available for segregation analysis.Clinical Characteristics
Those with ('PKD2') and those without ('non-PKD2') a
PKD2 mutation were grouped for further analysis. Indi-
cations for initial diagnostic abdominal ultrasonography
are given in Figure 2, and clinical characteristics in
Table 3. There was no significant difference between the
PKD2 and non-PKD2 groups when comparing range ofce. Mutations described in this report have been combined with
non-sense, frame-shift and insertion/deletion mutations).
e total coding sequence (blue).
Table 3 Characteristics of ADPKD patients screened for
PKD2 mutations. ns = not significant
Non-PKD2 PKD2 p-value
Number (%) 115 (80.3) 27 (19.7)
Male:female 0.59 0.59
Age at clinic presentation y 49.0 ± 13.3 49.5 ± 14.8 ns
Age at diagnosis y 37.4 ± 15.4 42.6 ± 14.4 ns
Hypertensive at diagnosis % 42.6 40.7 ns
Treatment for hypertension % 84.3 70.4 ns
Progression to ESRF % 12.2 0 p< 0.03
eGFR at presentation
ml/min/1.73 m2
67.0 ± 27.6 74.0 ± 28.4 ns
No FH of ADPKD % 35.6 25.9 ns
FH with ESRF % 50.4 40.7 ns
FH with no ESRF % 13.9 33.4 p< 0.03
Median age of family
member at ESRF y (range)
54.1 (33–83) 65.5 (50–86) p<0.0001
Number with FH ESRF< 50 yrs 31 0
Number with FH ESRF< 60 yrs 69 4
Number with FH ESRF< 70 yrs 81 9
Number with FH ESRF≥ 70 yrs 8 6
Number of family members









































Figure 3 Change in eGFR values over time (age in years) for
individuals with (A) and without (B) a PKD2 mutation..
Table 4 By-category comparison between genotypes of
proportion of cases developing CKD
Proportion % p-value
At least CKD3 Non-PKD2 48/105 46 0.15
PKD2 8/25 32
At least CKD4 Non-PKD2 23/105 22 0.21
PKD2 3/25 12
CKD5 or RRT Non-PKD2 14/105 13 0.04
PKD2 0/25 0
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sis, proportion with hypertension before or during fol-
low-up, or serum creatinine/eGFR at clinic presentation
(Table 3). Renal volume data were not available.
Serial renal function data were available for 130 of the
original 142 cases, a similar percentage in each group. A
total of 2103 creatinine values were recorded for 25
PKD2 and 105 non-PKD2 mutation carriers, with a me-
dian 12 (6–22) values per patient, representing renal
outcome data for 48.3 patient years for PKD2 and 49.5
patient years for non-PKD2 (Figure 3). No PKD2 patient
progressed to ESRF during follow-up, compared to 14
(13%) of the non-PKD2 group. In addition, 20/105 (19%)
non-PKD2 vs. 1/25 (4%) PKD2 patients had, or devel-
oped, at least CKD3 under the age of 40 years (p= 0.08).
For the whole group the proportion developing CKD3/4
was not significantly greater within the non-PKD2 group
(Table 4), and the median age at development of CKD3
was not dependent on PKD2 mutation status. Absence
of a PKD2 mutation was associated with a non-
significant trend towards a greater hazard of developing
CKD3, (HR 1.45; 0.68-3.07, P= 0.33, Figure 4) even when
adjusting the model for gender and hypertension
(HR 1.54; 0.73-3.29, P=0.26) (Additional file 2: Table S2).
Once CKD3 had developed, the rate of decline in renal
function (ml/min/year) for non-PKD2 and PKD2 cases
was similar (non-PKD2: 3.3 (2–5.5), PKD2: 2.2 (0.8 - 3.5),
p= 0.1 (Figure 5)).The number of patients reporting no known family
history of ADPKD did not differ significantly between
genotypes (36% of non-PKD2 and 26% of PKD2, Table 3);
neither did the occurrence within the family of ESRF
(Table 3). However, patients with a PKD2 mutation were
more likely to have a FH featuring preservation of renal
function (33.4% vs 13.9%, p < 0.03) and ESRF occurring
at an older age in affected relatives (65.5 ± 10.2 yrs vs
54.1 ± 9.8 yrs, p < 0.0001). No patient with a FH of ESRF
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Figure 4 Likelihood of development of CKD3 according to age
and genotype. (A) The hazard function estimates the event rate at
a given age, conditional on event-free survival to that age. The
greatest and smallest estimated hazard of developing CKD3 was
associated with non-PKD2 male hypertensive subjects and PKD2
female normotensive subjects. Although this is congruent with point
estimates from a multivariate Cox proportional hazards model
(Additional file 2: Table S2), these factors did not reach statistical
significance in this cohort. (B) Kaplan-Meier estimates of time to
CKD3..
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occur until at least 70 years was predictive of a PKD2
mutation (PPV 88%, sensitivity 0.29).Discussion
This preliminary, single centre, small scale prospective
study was designed to evaluate the use of routine PKD2
mutation testing in a nephrology outpatient clinic. The
clinic does not see those who have already developed
ESRF. Since it is known that PKD2 status identifies those
with a milder clinical phenotype and delayed progression
to ESRF by up to 20 years [7], this information would be
valuable to provide patients and their families with
improved prognostic information in the earlier stages of
their disease and to determine whether there were othersimple, patient-reported variables that could be used to
predict genotype and prognosis. Therefore additional
information about PKD1 mutation status was not
required, as assignment to the PKD2 group did not
require this. Similarly, the role of reduced-penetrance
PKD1 alleles on the expression of PKD2-linked disease
is not known and has not been evaluated in other
studies [19,20]. Patients carrying both PKD1 and PKD2
pathogenic mutations are also very rare [21].
We demonstrated that a fifth of an unselected ADPKD
patient cohort from a single clinic that sees patients
only with eGFR > 15 mL/min/1.73 m2 had a likely
pathogenic PKD2 mutation. Our patient characteristics
are very similar to those reported by Garcia-Gonzalez
et al. (2007), although the number reaching end-stage
was lower in our study (10% vs. 21%) [22]. In its de-
sign, our study was likely to favour a higher PKD2 de-
tection rate, as testing was not offered to individuals
with CKD5 or receiving RRT. In addition, defining the
proportion of all patients with ADPKD harbouring a
PKD2 mutation was not a primary aim of this study.
Consistent with this, other studies have shown a detec-
tion rate of ~15% when all prevalent cases have been
included. Therefore the conclusions of this study can
only be applied to similar clinical cohorts. As patients
with ADPKD and CKD1-4 are typically seen in the
nephrology out-patient clinic setting that does not in-
clude those with CKD5 and ESRF, this should not
present significant clinical difficulty.
Interestingly, there appeared to be no overall differ-
ence between the two groups in the risk of developing,
or age of development of, CKD3 or CKD4, or in the rate
of functional deterioration (eGFR) once CKD had super-
vened. It is unclear whether the former was due to the
cohort size or selection of patients with a milder pheno-
type due to the exclusion of those that presented with
CKD5. Post-hoc power calculations demonstrated that
the sample had 60% power to detect a renal survival dif-
ference for CKD3. For 80% power a sample size of 169
patients would be required (34 with a PKD2 mutation
and 135 without). Therefore the relatively small sample
size will limit some of the inferences that can be drawn
from our data. Although the proportion of patients
developing CKD3/4 in the two groups were not statisti-
cally different, we recognise that our study was sub-
optimally powered to detect such a difference, but the
direction of the effect of non-PKD2 status would be con-
sistent with previous reports of worse renal outcomes in
this patient group. There was greater heterogeneity in
the renal phenotype of non-PKD2 patients, with a mi-
nority experiencing early-onset CKD (Figure 3). Further
well- powered longitudinal studies in the same clinical
setting, using multi-centre registries of genotyped







































After onset of CKD3
Change in Renal Function
A
B
Figure 5 Box plots (median, lower and upper quartiles and
range) of rate of change in eGFR during follow-up: (A)
according to genotype and (B) after onset of CKD3..
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hypertension and albuminuria.
Currently, genic variation in ADPKD is the main
factor predicting renal outcome, ESRF occurring up to
15–20 years later in patients with a PKD2 mutation
when compared to those with a PKD1 mutation [7].
MRI imaging data from the CRISP study suggests that
this is due to a lower number of cysts being present in
PKD2-related disease, rather than differences in the rate
of cyst growth or renal enlargement [23,24]. Although
not generally in clinical use, measurement of single or
serial renal volumes may better predict disease severity,
with larger kidneys predicting a more rapid rate of de-
cline in GFR [23]. However, routine PKD2 mutation
testing that does not require the patient to be present,
will become more economical and identifies a group of
patients likely to have preserved renal function for
longer [18].
The use of direct mutation testing rather than linkage
analysis also has the benefit of being available to indivi-
duals rather than extended families. About a third ofour cohort was not aware of a FH of ADPKD at the
time of clinic attendance and would therefore not have
been suitable for linkage analysis. This most likely
represents a combination of factors including new mu-
tation, undiagnosed disease in relatives and unrevealed
diagnoses rather than a higher than expected new muta-
tion rate alone. Whilst the lack of a FH means that the
Ravine criteria for the diagnosis of ADPKD cannot be
strictly employed it is likely that other causes of PKD,
such as renal cysts and diabetes (RCAD, OMIM 137920)
which can phenocopy ADPKD, were not sufficiently
common to account for the discrepancy with the
published data. Similarly the role of hypomorphic
alleles in modifying disease presentation remains un-
known although is unlikely to account for significant
non-penetrance. In the study by Barua et al. [25], the
new mutation rate determined following parental ultra-
sound examination was ~10%, suggesting that in more
than a fifth of our patients, a diagnosis of ADPKD is not
being communicated or is undiagnosed. Wider use of
parental screening after appropriate counselling is there-
fore justified to clarify disease risks for family members.
Further work will be required to explore how this may
be more generally implemented in non-specialist clinics
and in primary health care.
The detection rate of ~ 20% PKD2 mutations is in
broad agreement with other studies (range 15-36%;
Table 1) [5,6,12,13,22,25,26]. However, each of these
studies employed different inclusion and exclusion cri-
teria and sampled different populations, making ascer-
tainment bias likely. The estimate of 36% in one study
may represent the true frequency when population
screening for ADPKD is carried out, and would likely
represent the ascertainment of asymptomatic, undiag-
nosed and therefore mild cases.
Unlike direct PKD1 mutation testing, where it remains
difficult to assign pathogenicity to some variants, the
majority of PKD2 sequence variants can be assigned as
likely or highly likely to be pathogenic [12,13]. Sensitivity
of mutation detection is therefore likely to be very high
when using direct sequencing, although this needs to be
formally tested in families where linkage data are also
available [25]. In the study by Veldhuisen et al. (1997),
mutations were found in 57% of 35 families linked to the
PKD2 locus when 80% of the gene was screened by sin-
gle strand conformation polymorphism analysis and dir-
ect sequencing [27]. With newer methods and complete
gene sequencing and dosage analysis, a higher detection
rate is likely. Our figure of ~ 20% may therefore still
slightly underestimate the true number of PKD2 muta-
tions in this cohort of patients with CKD1-4. Dosage
analysis is now available and should be included in fu-
ture studies. However, the PKD Mutation Database sug-
gests that large deletions and duplications in PKD2 are
Robinson et al. BMC Nephrology 2012, 13:79 Page 8 of 10
http://www.biomedcentral.com/1471-2369/13/79rare. Only a single deletion among 115 pathogenic
PKD2 mutations reported here and in the database
would have been missed without dosage analysis. Thus
a > 98% detection rate by screening coding exons and
their splice sites can be achieved. This represents the
best current method for identifying individuals and fam-
ilies that harbor a PKD2 mutation and may therefore
have a better prognosis.
Although molecular testing for ADPKD is now available
in the UK (www.ukgtn.org.uk), it has not been routinely
used in nephrology out-patient clinics for diagnostic, pre-
dictive or prognostic testing. At present, diagnosis and
family screening are almost exclusively carried out using
imaging combined with a FH. The main utility of genetic
testing to date has been in research to define the natural
history of the disease by genotype, and to identify geno-
type/phenotype correlations [26]. Indications for clinical
molecular testing include establishment of the correct
diagnosis if there is no family history and if there are
atypical features on imaging; exclusion testing for poten-
tial living-related donors and prenatal/pre-implantation
genetic diagnosis [28]. Of these, the ~ 20% detection rate
of PKD2 mutations is likely to be most clinically useful in
screening potential living-related donors, particularly for
those with normal ultrasounds below age 40 [14]. Non-
PKD2 status is assumed here to represent PKD1-linked
disease, i.e. in this context the test is 100% specific and
sensitive.
Of the clinical variables recorded in this study, few
had significant predictive power to identify patients
likely to have a PKD2 mutation. In the multivariate
model adjusting for gender and hypertension, point esti-
mates suggested that non-PKD2 disease, male gender
and the presence of hypertension may together be asso-
ciated with earlier onset of CKD3 (Additional file 2:
Table S2), although formal significance levels were not
reached in this cohort due to its size. However, the dir-
ectional nature of the effect supports previous reports
indicating a milder renal phenotype with PKD2 muta-
tions [18].
The lack of difference in progression from CKD3 be-
tween the two groups was unexpected, but may be due
to a number of factors. Firstly, although 16 non-PKD2
cases had developed CKD4 earlier than the youngest
PKD2 case with CKD4 (59.6 years), 25% (5/20) of non-
PKD2 cases had not yet reached CKD3 by the age of
62, compared to 17% (1/6) of PKD2 cases, further high-
lighting that likely PKD1 mutations may be associated
with mild disease [20]. Secondly, our analysis may
underestimate progression of CKD in non-PKD2 cases
due to ascertainment bias through exclusion of patients
with existing CKD5/ESRD, since our results suggest a
predominance of non-PKD2 in patients in this group.
Thirdly and most likely, our available sample may beunderpowered to detect differences in progression to
CKD3. This further emphasises the continued need to
conduct long-term studies on large, genotyped cohorts.
However, the comparable rate of decline in eGFR after
the onset of CKD3 between the two groups is similar to
that observed in previous studies where no significant
differences between genotypes were found, suggesting
that the underlying disease process is independent of the
causal mutation [23]. This is also supported by previ-
ously observed similar rates of change in renal volume
between PKD1 and PKD2 groups, although the PKD2
group have fewer cysts and smaller kidneys at a given
age [24].
The predictive value of the FH was strong [25].
PKD2 patients were more likely to have a FH of
ADPKD without progression of CKD, and the average
age of a family member with ESRF was significantly
higher than the non-PKD2 group (Table 3). This reflects
the ascertainment of all degrees of disease among family
members and is in keeping with the previously reported
milder clinical phenotype of PKD2-linked disease [7]. A
FH of ESRF before age 50 was highly predictive of non-
PKD2 status (PPV 100%, sensitivity 0.71). Therefore, in
PKD patients with relatively preserved renal function,
the disease course of affected family members can use-
fully be used to direct genetic testing, with PKD2 testing
targeted to those patients with a FH of ESRF occurring
only over 50 yrs. Similarly, a FH of ESRF occurring at
or after age 70 was strongly predictive of a PKD2 muta-
tion (PPV 88%, sensitivity 0.29). However, sensitivity
was low, as some individuals with apparent PKD1-linked
disease (non-PKD2) can have very mild disease [29], as
observed in our cohort (Figure 3). Our results confirm
those of Barua et al. who found that the presence of at
least one family member who developed ESRF before
55 years was highly predictive of PKD1 (positive pre-
dictive value 100%, sensitivity 72%) [25]. Having at least
one family member with ESRF after 70 years of age was
also highly predictive of PKD2 in that study. FH alone
has limitations if additional family information is not
available, or if an individual represents a new mutation
(i.e. if both parents have normal renal imaging). Such
patients are suitable for genetic analysis.
Importantly, a positive PKD2 test allows other family
members to consider predictive genetic testing. There-
fore, whilst a detailed FH has some predictive value and
patients with a FH of ESRF before age 50 can be
excluded from PKD2 testing, genotyping offers the best
means to provide prognostic information in the absence
of other discriminant clinical parameters. In summary,
we suggest that PKD2 screening can be routinely offered
to ADPKD patients except where they or their family
members have developed ESRF under age 50. Additional
studies in larger cohorts or using pooled data analysis
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and criteria for PKD gene testing.
Conclusions
In this study we have used mutation analysis to identify
a group of patients with pathogenic PKD2 mutations but
preserved renal function. PKD2 mutations have previ-
ously been reported to confer substantially better renal
survival compared to PKD1-linked disease, making this
an important prognostic marker. We have shown that in
a population of patients with CKD1-4, PKD2 testing was
positive in about a fifth of patients. When used alone, it
could not discriminate those individuals with milder
renal disease defined by stage of CKD, but did identify a
group less likely to progress to ESRF. Combined with
FH, it offers useful prognostic information for indivi-
duals and their families, and can be routinely offered to
all but those whose relatives have developed ESRF before
the age of 50.
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